Healthcare Stocks on Investor Radars Before Earnings This Week

Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Coventry Health Care, Inc. (NYSE:CVH) will unveil its latest earnings on Wednesday, February 8, 2012. The average estimate of analysts is for net income of 64 cents per share, a decline of 33.3% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting profit of $2.93 per share, a decline of 20.8% from last year.

Last quarter, the company beat estimates by 3 cents, coming in at net income of 84 cents a share versus the estimate of profit of 81 cents a share. It marked the fourth straight quarter of beating estimates. On average, analysts predict $3.09 billion in revenue this quarter, a rise of 2% from the year ago quarter. Analysts are forecasting total revenue of $12.14 billion for the year, a rise of 4.7% from last year’s revenue of $11.59 billion.

Competitors to Watch: UnitedHealth Group Inc. (NYSE:UNH), Aetna Inc. (NYSE:AET), Health Net, Inc. (NYSE:HNT), WellCare Health Plans, Inc. (NYSE:WCG), Universal American Corp. (NYSE:UAM), WellPoint, Inc. (NYSE:WLP), CIGNA Corporation (NYSE:CI), Humana Inc. (NYSE:HUM), Centene Corporation (NYSE:CNC), and Magellan Health Services, Inc. (NASDAQ:MGLN).

Neurocrine Biosciences Inc. (NASDAQ:NBIX) will unveil its latest earnings on Wednesday, February 8, 2012. The average estimate of analysts is for profit of one cent per share, a decline of 75% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 20 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at one cent during the last month. For the year, analysts are projecting net income of 66 cents per share, a swing from net loss of 16 cents last year.

Last quarter, the company came in at profit of 56 cents per share against a mean estimate of net income of 9 cents per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 2 cents. On average, analysts predict $12.1 million in revenue this quarter, a decline of 11.6% from the year ago quarter. Analysts are forecasting total revenue of $78.4 million for the year, a rise of more than twofold from last year’s revenue of $33.5 million.

Competitors to Watch:
GlaxoSmithKline plc (NYSE:GSK), Abbott Laboratories (NYSE:ABT), Repligen Corporation (NASDAQ:RGEN), Pfizer Inc. (NYSE:PFE), EntreMed, Inc. (NASDAQ:ENMD), Johnson & Johnson (NYSE:JNJ), Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), Forest Laboratories, Inc. (NYSE:FRX), and Repros Therapeutics Inc. (NASDAQ:RPRX).

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com

More Articles About:
Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business